PCRC_A221805

Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study

This phase II/III trial studies the best dose of duloxetine and how well it works in preventing pain, tingling, and numbness (peripheral neuropathy) caused by treatment with oxaliplatin in patients with stage II-III colorectal cancer. Duloxetine increases the amount of certain chemicals in the brain that help relieve depression and pain. Giving duloxetine in patients undergoing treatment with oxaliplatin for colorectal cancer may help prevent peripheral neuropathy.

Key Eligibility:

• Stage II-III colorectal cancer patients.
• 25 Years of age and older.
• No pre-existing clinical or pre-clinical peripheral neuropathy from any cause.
• No symptoms of or history of schizophrenia, bipolar disease, suicidal thoughts and/or a major depression.
Phase II/III
NCT04137107
Oncology
Gastrointestinal
Alison Conlin, M.D.
Alliance
Mary Mccormick

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.